You're signed outSign in or to get full access.
Siren, L.L.C.
SIREN, L.L.C. is an institutional investment manager headquartered in New York, NY. The firm operates as a hedge fund and is associated with The Invus Group, LLC. SIREN, L.L.C. files regulatory reports with the U.S. Securities and Exchange Commission, managing investments in public securities. Its filings indicate active investment management with a diversified portfolio valued in the billions. The firm is overseen by Raymond Debbane, who is listed as President in SEC documents. The entity is incorporated in Delaware. The number of employees is not specified in public filings; further public resources do not confirm a specific founding year, but the structure and reporting are typical of established hedge fund operations.
Investment Strategy
SIREN, L.L.C. implements an institutional, actively managed equity investment strategy, as indicated by its regular Section 13F filings detailing broad holdings across biotechnology, pharmaceutical, and high-growth sectors. The fund applies research-driven selection to pursue long-term growth and capital appreciation, reflecting flexibility to invest in both U.S. and international securities, often focusing on emerging opportunities and innovative industries. This strategy may also involve participation in public company engagements and special situations.
Latest 13F Filing Activity
Siren, L.L.C. filed their most recent 13F report on Jun 30, 2025 disclosing 108 equity positions with a total 13F market value of $2B. The fund increased holdings in Kymera Therapeutics Inc., Scholar Rock Holding Corp., Moonlake Immunotherapeutics among other positions. Siren, L.L.C. reduced exposure to Blueprint Medicines Corp., Newamsterdam Pharma Company NV, Prothena Corporation PLC among others.
Top Holdings
Equity Positions (108)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
S SRRK | Scholar Rock Holding Corp | 16.95% | $327.6M | 9,250,005 | $8.01 | $35.42 | +$30.2M |
K KYMR | Kymera Therapeutics Inc | 7.74% | $149.6M | 3,428,150 | $45.55 | $43.64 | +$60.9M |
I IRON | Disc Medicine Inc | 3.01% | $58.2M | 1,099,401 | $49.72 | $52.96 | +$5.0M |
C CRNX | Crinetics Pharmaceuticals Inc | 2.51% | $48.6M | 1,688,611 | $50.28 | $28.76 | -$8.1M |
B BCAX | Bicara Therapeutics Inc | 2.51% | $48.5M | 5,216,969 | $19.11 | $9.29 | +$5.9M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more